Abstract Up to 30% of patients taking antipsychotics may develop tardive dyskinesia (TD). Recent evidence-based recommendations demonstrate an unmet need for effective TD management. …

The VMAT-2 inhibitors are utilized for the management of chorea associated with Huntington Disease (HD) and for the management of tardive dyskinesia (TD). Tetrabenazine, the first …

Tetrabenazine, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, is licensed in the UK for the treatment of moderate to severe tardive dyskinesia. Benzodiazepines, amantadine, …

Oct 6, 2025 · Tardive dyskinesia (TD) is a medication-induced hyperkinetic movement disorder associated with the use of dopamine receptor-blocking agents, including first- and second …

Dec 1, 2022 · In conclusion, tardive dyskinesia appears as a side effect that should be carefully monitored, especially in elderly patients, due to the use of antipsychotics. Although there is …

Objective: Tetrabenazine, a monoamine depleter and dopamine receptor blocker, is used to treat several hyperkinetic movement disorders. The authors studied the use of tet-rabenazine for …

Jul 14, 2025 · Medications for Parkinsonism worsen tardive dyskinesia symptoms, and vice versa. Only 2 FDA-approved medications for tardive dyskinesia sit on the market—tetrabenazine and …

OBJECTIVE: To describe long-term experience with tetrabenazine (TBZ) in the treatment of tardive dyskinesias. BACKGROUND: Dopamine receptor blocking drugs, commonly used in …

Nov 7, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and …

Sep 18, 2023 · Tardive dyskinesia (TD) was diagnosed, and treatment with tetrabenazine (12.5 mg twice daily, titrated to 50 mg 3 times daily) was initiated. Although the tardive movements …